��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2004, 30(3) 149-151 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	ϸ��
	��
	��
	��˻�
	��
	PubMed
	Article by
	Article by

ϸ��м��е��о��չ

��˻�, ��

�Ͼ�ҽ�ƴ�ѧ��һ��ҽԺƤ�� 210029

ժҪ��

��м��ٴ��ĳ��,�䷢��в��ȫ��,��Ҳһֱû��ʵ��Ч�ķ��ϸ��м��е��Խ��Խ�ܵ��ע,��ϸ��Ƽ��ٴ��м��һЩϸ��м��е��о��չ��

�ؼ���� м�� ϸ��

Abstract:

Keywords:

�ո�� 2003-07-29 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 2002, 46:1-23.
[2] Ferenczi K, Burack L, Pope M, et al. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun,2000, 14:63-78.
[3] Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol, 2000, 136:675-676.
[4] Krueger JG, Walters lB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin .2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol, 2000, 43:448-458.
[5] Gottlieb AB, Bacha P, Parker K, et al. Use of the interleukin-2 (IL-2) fusion protein, DAB389 IL-2, for the treatment of psoriasis.Dermatol Ther, 1998, 5:48-63.
[6] Bagel J, Garland WT, Breneman D, et al. Administration of DAB3891L-2 to patients with recalcitrant psoriasis: a double-blind,phase I1 muhicenter trial. J Am Acad Dermatol, 1998, 38:938-944.
[7] Martin A, Gutierrez E, Muglia J, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB (389) IL-2) in patients with severe psoriasis. J Am Acad Dermatol, 2001, 45:871-881.
[8] Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type l inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol,2001, 116:319-329.
[9] Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest, 1998, 101:783-794.
[10] Asadullah K, Docke WD, Ebeling M,et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol, 1999,135:187-192.
[11] Friedrich M, Docke WD, Klein A, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol, 2002, 118:672-677.
[12] Bozza M, Bliss JL, Dorner AJ, et al. Interleukin-11 modulates Thl/Th2 cytokine production from activated CI4 + T cells. J Interferon Cytokine Res, 2001,21:21-30.
[13] Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest, 1999, 104:1527-1537.
[14] Leng SX, Elias JA. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol, 1997, 159:2161-2168.
[15] Trepicchio WL, Bozza M, Pedneault G, et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol, 1996, 157:3627-3634.
[16] Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol, 2002, 46:886-891.
[17] Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol, 2000, 42:829-830.
[18] Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.Lancet, 2001, 357:1842-1847.
[19] Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol, 2001, 144:587-589.
[20] Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol, 2002, 47:796-797.
[21] Keane J, Gershon S, Wise RP,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 2001, 345:1098-1104.
[22] Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol, 2002, 3:159-173.
[23] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 2000,356:385-390.
[24] Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol, 2000, 18:732-734.
[25] Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol, 2001, 137:893-899.